ICON audit found revenue was overstated in 2023 and 2024; Psilera and Secretome Therapeutics raise funds.
May 28, 2026 10:51 AM EDT
News Briefing
ICON audit finds overstated revenue; Secretome and Psilera raise cash
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Ahead of ASCO, all eyes on pancreatic cancer
XtalPi Receives Second Payment from DoveTree; First Oncology Asset Advances into IND-Enabling Studies
ASCO preview: With expectations jacked up, Akeso's ivonescimab to face scrutiny in high-stakes plenary
With Elahere building steam, AbbVie nets FDA nod for another ImmunoGen cancer asset
FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote
Five biotech news updates to stay on top of today
Fierce Pharma Asia—More China biotech hawkishness; Pfizer’s $10B Innovent deal; Astellas’ roadmap
Astellas eyes more cost cuts; FDA panel to debate Moderna vaccine
Allogene CEO to step down; Agios drug fails key test
AstraZeneca seeks a narrower path for failed antibody; Imfinzi and Tremfya label expansions
Cartesian’s $150M financing; Editas Medicine’s money moves
Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform; CREATE Medicines raises…
Strong results from GSK's hepatitis B drug, engineered heart patches, and more biotech news from The Readout
Assertio’s latest offer represents a roughly 31% premium over an initial acquisition proposal. Elsewhere, Kyverna is readying a…
Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The Readout
